Nurix Therapeutics (NRIX) Cash from Investing Activities Growth (1y) (2020 - 2026)
Powered by 
Analysis
Nurix Therapeutics (NRIX) Cash from Investing Activities Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 26.37% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -89.24% |
| 10 | Nurix Therapeutics | 2.90 Bn | 2.46 Bn | - | 30.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | 30.07% |
| Feb 28, 2026 | -584.96% |
| Nov 30, 2025 | 100.25% |
| Aug 31, 2025 | 336.54% |
| May 31, 2025 | 154.55% |
| Feb 28, 2025 | -28.10% |
| Nov 30, 2024 | -879.73% |
| Aug 31, 2024 | -193.69% |
| May 31, 2024 | -399.03% |
| Feb 29, 2024 | 121.02% |
| Nov 30, 2023 | -126.13% |
| Aug 31, 2023 | 136.11% |
| May 31, 2023 | 1,019.85% |
| Feb 28, 2023 | -59.86% |
| Nov 30, 2022 | 250.61% |
| Aug 31, 2022 | -415.71% |
| May 31, 2022 | 91.66% |
| Feb 28, 2022 | 1,777.04% |
| Nov 30, 2021 | 70.68% |
| Aug 31, 2021 | 88.68% |